A Retrospective Trial Exploring Erzhu Yiren Decoction in Gastric Ulcer with Spleen Deficiency and Dampness-Heat
CONCLUSION: Erzhu Yiren Decoction can relieve the clinical symptoms of patients with gastric ulcers of spleen deficiency and dampness heat; improve the serum NO, EGF, and PGE2 levels; optimize the mucosal maturity; and enhance the overall efficacy, which merits clinical promotion.PMID:35178451 | PMC:PMC8844433 | DOI:10.1155/2022/6495181 (Source: Biomed Res)
Source: Biomed Res - February 18, 2022 Category: Research Authors: Ting Zhang Zhaowei Shan Source Type: research
A Retrospective Trial Exploring Erzhu Yiren Decoction in Gastric Ulcer with Spleen Deficiency and Dampness-Heat
CONCLUSION: Erzhu Yiren Decoction can relieve the clinical symptoms of patients with gastric ulcers of spleen deficiency and dampness heat; improve the serum NO, EGF, and PGE2 levels; optimize the mucosal maturity; and enhance the overall efficacy, which merits clinical promotion.PMID:35178451 | PMC:PMC8844433 | DOI:10.1155/2022/6495181 (Source: Biomed Res)
Source: Biomed Res - February 18, 2022 Category: Research Authors: Ting Zhang Zhaowei Shan Source Type: research
A Retrospective Trial Exploring Erzhu Yiren Decoction in Gastric Ulcer with Spleen Deficiency and Dampness-Heat
CONCLUSION: Erzhu Yiren Decoction can relieve the clinical symptoms of patients with gastric ulcers of spleen deficiency and dampness heat; improve the serum NO, EGF, and PGE2 levels; optimize the mucosal maturity; and enhance the overall efficacy, which merits clinical promotion.PMID:35178451 | PMC:PMC8844433 | DOI:10.1155/2022/6495181 (Source: Biomed Res)
Source: Biomed Res - February 18, 2022 Category: Research Authors: Ting Zhang Zhaowei Shan Source Type: research
Identification and genotoxicity evaluation of potential impurities in rabeprazole sodium using in silico and in vitro analyses
Volume 45, Issue 5, September 2022, Page 2116-2122 . (Source: Drug and Chemical Toxicology)
Source: Drug and Chemical Toxicology - April 8, 2021 Category: Toxicology Authors: Yi Du Yinnan Wu Yang Liu Changhong Meng Li Tan Tiantian Cai Yuxin Wang Yihong Lu Source Type: research
Identification and genotoxicity evaluation of potential impurities in rabeprazole sodium using in silico and in vitro analyses
. (Source: Drug and Chemical Toxicology)
Source: Drug and Chemical Toxicology - April 8, 2021 Category: Toxicology Authors: Yi Du Yinnan Wu Yang Liu Changhong Meng Li Tan Tiantian Cai Yuxin Wang Yihong Lu Source Type: research
Levothyroxine-sodium/rabeprazole/sodium-valproate
(Source: Reactions Weekly)
Source: Reactions Weekly - November 1, 2020 Category: Drugs & Pharmacology Source Type: research
Does Rabeprazole Sodium Alleviate the Anti-diabetic Activity of
Linagliptin? Drug-Drug Interaction Analysis by In vitro and In vivo
Methods
Drug Res (Stuttg) DOI: 10.1055/a-1233-3371Drug interaction has turned into the preeminent regarding issues for a prescriber
during polypharmacy. The foremost objective of this research was to form a
complex between linagliptin and rabeprazole sodium by in vitro
interactions. The interactions between the drugs have been examined by
monitoring some chromatographic and spectroscopic analyses viz. TLC, HPLC,
FT-IR, UV, Job’s plot, conductometric titrations, and Ardon’s
spectrophotometric strategy. Rabeprazole sodium formed a stable complex with
linaglipt...
Source: Drug Research - September 10, 2020 Category: Drugs & Pharmacology Authors: Hossain, Md. Jamal Sultan, Md. Zakir Rashid, Mohammad A. Kuddus, Md. Ruhul Tags: Original Article Source Type: research
Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication
AbstractTo evaluate the efficacy and economics of different proton pump inhibitors (PPIs) combined with bismuth quadruple regimens forHelicobacter pylori (Hp) eradication, a retrospective analysis method was used to collect Hp-positive patients who were treated with a bismuth-containing quadruple regimen (PPIs + amoxicillin + furazolidone + colloid pectin bismuth) from the outpatient department of gastroenterology in our hospital from January to June 2017. A total of 1410 patients were included in the study and divided into four groups according to different PPIs: group A (pantoprazole sodium enteric-coated ca...
Source: Clinical and Experimental Medicine - July 9, 2020 Category: Research Source Type: research
The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors.
Abstract
The major therapeutic strategy for acid-related gastrointestinal diseases in clinic is to reduce the excretion of gastric acid by oral administration of proton-pump inhibitors (PPIs). However, it is quite a challenge to study the oral absorption behaviors of PPIs considering their extreme instability under gastrointestinal environment. As a result, little information has been reported on PPI oral absorption so far, hindering the further development of PPI-contained oral preparations. Here, we first investigated the degradation rate of three representative PPIs, including ilaprazole, ilaprazole sod...
Source: European Journal of Pharmaceutics and Biopharmaceutics - January 29, 2020 Category: Drugs & Pharmacology Authors: Shen T, Jiang X, Jin Z, Ji Q, Li C, Li Q, Long H, Qiu W, Wang W, Hou X, You J Tags: Eur J Pharm Biopharm Source Type: research
Patients Should Not Swallow AcipHex Sprinkle Capsules!
No abstract available (Source: Home Healthcare Nurse)
Source: Home Healthcare Nurse - January 1, 2020 Category: Nursing Tags: ISMP MEDICATION SAFETY Source Type: research
Stereoselective pharmacokinetics of (R)-(+)- and (S)-(-)-rabeprazole in human using chiral LC-MS/MS after administration of rabeprazole sodium enteric-coated tablet.
Abstract
Rabeprazole is an effective proton pump inhibitor to treat acid-related diseases. To achieve the simultaneous determination of rabeprazole enantiomers in human plasma, a chiral LC-MS/MS method was developed and validated. Acetonitrile including 0.1% ammonium were used as protein precipitating agent. Analytes were separated within 8 minutes on a Chiralpak IC column (4.6 mm × 150 mm, 5 μm). The mobile phase was 10 mM ammonium acetate including 0.2% acetic acid-acetonitrile (35:65, v/v). An API 4000 mass spectrometer was used as detector for the analysis, and the multiple reactions monitorin...
Source: Chirality - October 15, 2018 Category: Molecular Biology Authors: Sun LN, Shen YW, Ying YW, Li D, Li TF, Zhang XH, Zhao P, Ding L, Wang YQ Tags: Chirality Source Type: research
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study
ConclusionsZ-215 was as effective and well tolerated as 10 mg RPZ in the treatment of RE in this selected population. CYP2C19 genotype status may not influence the efficacy and safety of Z-215. There were no clear dose–response effects between Z-215 doses in the endoscopic healing of RE. These findings suggest that Z-215 may be 1 option for the initial treatment of RE. ClinicalTrials.gov identifier: NCT 02463643. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - July 10, 2018 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study
Conclusions Z-215 was as effective and well tolerated as 10 mg RPZ in the treatment of RE in this selected population. CYP2C19 genotype status may not influence the efficacy and safety of Z-215. There were no clear dose–response effects between Z-215 doses in the endoscopic healing of RE. These findings suggest that Z-215 may be 1 option for the initial treatment of RE. ClinicalTrials.gov identifier: NCT 02463643. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - April 13, 2018 Category: Drugs & Pharmacology Source Type: research
